

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

Capan-1

RRID:CVCL_0237

Type: Cell Line

Proper Citation

RRID:CVCL_0237

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0237

Proper Citation: RRID:CVCL_0237

Description: Cell line Capan-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic ductal adenocarcinoma

Defining Citation: [PMID:327080](#), [PMID:833871](#), [PMID:1764370](#), [PMID:3518877](#), [PMID:6278935](#), [PMID:6582512](#), [PMID:6935474](#), [PMID:7017212](#), [PMID:7459858](#), [PMID:8026879](#), [PMID:8286197](#), [PMID:8426738](#), [PMID:8968085](#), [PMID:9331070](#), [PMID:10027410](#), [PMID:10408907](#), [PMID:11169957](#), [PMID:11668190](#), [PMID:12692724](#), [PMID:14695172](#), [PMID:15162061](#), [PMID:15367885](#), [PMID:16912165](#), [PMID:18264088](#), [PMID:18298655](#), [PMID:18380791](#), [PMID:20037478](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20418756](#), [PMID:21750719](#), [PMID:22109279](#), [PMID:22460905](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: TCGA-110-CL cell line panel., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Capan-1

Synonyms: CaPan-1, CAPAN-1, Capan 1, CAPAN 1, Capan1, CAPAN1

Cross References: BTO:BTO_0002744, CLO:CLO_0002197, EFO:EFO_0002153, MCCL:MCC:0000126, CLDB:cl639, CLDB:cl640, AddexBio:C0018001/31, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-79, BCRJ:0265, BioGRID_ORCS_Cell_line:844, BioSample:SAMN01821543, BioSample:SAMN01821620, BioSample:SAMN03471999, BioSample:SAMN05292467, BioSample:SAMN10987884, cancercellines:CVCL_0237, CancerTools:161907, Cell_Model_Passport:SIDM00934, CGH-DB:162-1, CGH-DB:9269-4, ChEMBL-Cells:ChEMBL3307640, ChEMBL-Targets:ChEMBL614536, CLS:300143, Cosmic:724646, Cosmic:736270, Cosmic:753624, Cosmic:755302, Cosmic:808173, Cosmic:872997, Cosmic:913302, Cosmic:922252, Cosmic:923166, Cosmic:932516, Cosmic:933521, Cosmic:947395, Cosmic:948374, Cosmic:948726, Cosmic:949231, Cosmic:1006365, Cosmic:1090399, Cosmic:1108338, Cosmic:1122342, Cosmic:1198205, Cosmic:1299296, Cosmic:1320462, Cosmic:1534317, Cosmic:1571774, Cosmic:1761694, Cosmic:1995362, Cosmic:2434105, Cosmic-CLP:753624, DepMap:ACH-000354, DSMZ:ACC-244, DSMZCellDive:ACC-244, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:753624, GEO:GSM206452, GEO:GSM383933, GEO:GSM621902, GEO:GSM784706, GEO:GSM886920, GEO:GSM887986, GEO:GSM1024398, GEO:GSM1374438, GEO:GSM1374439, GEO:GSM1669663, IARC_TP53:1560, IGRhCellID:Capan1, IZSLER:BS TCL 9, KCLB:30079, LiGeA:CCL_751, LINCS_LDP:LCL-1732, Lonza:1011, PharmacDB:CAPAN1_184_2019, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL_0237, PubChem_Cell_line:CVCL_0237, SKY/M-FISH/CGH:1999, TOKU-E:773, Wikidata:Q54808589

ID: CVCL_0237

Record Creation Time: 20220427T215440+0000

Record Last Update: 20260829T231753+0000

Ratings and Alerts

No rating or validation information has been found for Capan-1.

No alerts have been found for Capan-1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 396 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Safari M, et al. (2026) Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy*, 84, 101312.

Jia A, et al. (2026) Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD⁺ to eradicate KRAS-driven AML. *Cell metabolism*, 38(6), 1113.

Kopp A, et al. (2026) In Vivo Auto-tuning of Antibody-Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies. *Molecular cancer therapeutics*, 25(4), 610.

Yang J, et al. (2026) A Malignant Subpopulation of H2AFZ⁺ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(12), 2479.

Yadav K, et al. (2026) Therapeutic targeting of GSK-3 β activation by the tyrosine kinase RYK in pancreatic ductal adenocarcinoma with BJ-2412, a novel sunitinib analogue. *British journal of pharmacology*, 183(15), 4196.

Anh DXT, et al. (2026) GlycoChat Uncovers Glycan-Lectin Circuits in the Tumor Microenvironment of Pancreatic Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(14), e14735.

Kaur T, et al. (2026) Loss of Regulator of G Protein Signaling 11 Promotes Protumorigenic Features in Pancreatic Cancer. *Molecular cancer research : MCR*, 24(1), 34.

Kong C, et al. (2026) Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation. *Communications biology*, 9(1).

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. *Molecular cancer therapeutics*, 25(1), 7.

Shi M, et al. (2026) Transcriptomic landscape of transposable elements reveals LTR7-PLAAT4 as a potential oncogene and therapeutic target in pancreatic adenocarcinoma. *Genome research*, 36(2), 275.

Kwon YJ, et al. (2026) Basroparib inhibits YAP-driven cancers by stabilizing angiotensin. *Molecular oncology*, 20(5), 1284.

Musiani D, et al. (2025) Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors. *Molecular cell*, 85(6), 1072.

Chang TY, et al. (2025) Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy. *Scientific reports*, 15(1), 8735.

Song L, et al. (2025) Dynamic control of RNA-DNA hybrid formation orchestrates DNA2 activation at stalled forks by RNAPII and DDX39A. *Molecular cell*, 85(3), 506.

Cerqua M, et al. (2025) The integrated stress response drives MET oncogene overexpression in cancers. *The EMBO journal*, 44(4), 1107.

Anastasio G, et al. (2025) Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors. *iScience*, 28(2), 111842.

Tang J, et al. (2025) CD44 identified as a diagnostic biomarker for highly malignant CA19-9 negative pancreatic cancer. *Cancer letters*, 622, 217713.

Vandenbussche N, et al. (2025) EMT-associated bias in the Parsortix?? system observed with pancreatic cancer cell lines. *Molecular oncology*.

Kang HW, et al. (2025) SLC6A14-mediated glutamine promotes SYTL4-CXCL8 axis activation to drive gemcitabine resistance and immune evasion in pancreatic cancer. *Experimental & molecular medicine*, 57(12), 2943.

Zhang S, et al. (2025) Vitamin D Binding Protein, a Ligand of Integrin beta 1, Motivates Both Tumor Cells and Schwann Cells to Promote Perineural Invasion in Pancreatic Ductal Adenocarcinoma. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e11726.